Boston- May 22, 2024- Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, announced the expansion of its executive team with the appointments of Serena Hung, M.D., as chief medical officer, and Jeffrey Young as chief financial officer. Dr. Hung is a board-certified neurologist who has held leadership roles at prominent CNS drug development companies, and Mr. Young is a seasoned financial executive with capital markets expertise and with over two decades of experience in life sciences.
“We are thrilled to welcome Jeffrey and Serena to Atalanta’s executive team as we prepare for our next phase of growth in building the leading CNS RNAi company,” said Alicia Secor, Atalanta’s president and chief executive officer. “Atalanta’s discovery efforts utilize our best-in-class di-siRNA platform and have generated a robust portfolio of 14 current programs across our wholly-owned and partnered pipelines. Jeffrey’s leadership will help shape Atalanta’s strategic direction and drive our continued sustainable growth, while Serena’s expertise will support the transition from research to development for two of our wholly-owned programs which we are advancing to planned IND submissions in 2025, with a third to follow.”
Also Read: Blue Shield of California Appoints Senior Executives
“Disease-modifying therapeutic options for neurological diseases are tragically limited, and I observed this firsthand in my years as a clinician specializing in Huntington’s and Parkinson’s diseases,” said Dr. Hung. “I believe Atalanta’s novel RNAi platform could provide a much-needed breakthrough to deliver better outcomes for these patients.”
“Atalanta’s di-siRNA technology has potential to unlock a large universe of CNS targets, and their pipeline progress underscores that they have the operational acumen to realize this potential for patients,” said Mr. Young. “I’m looking forward to strategically supporting and growing our programs to ensure continued success.”
